- Home
- NYAX vs ETNB Comparison
NYAX vs ETNB Comparison
Compare NYAX & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYAX
- ETNB
- Stock Information
- Founded
- NYAX 2005
- ETNB 2018
- Country
- NYAX Israel
- ETNB United States
- Employees
- NYAX N/A
- ETNB N/A
- Industry
- NYAX
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- NYAX
- ETNB Health Care
- Exchange
- NYAX Nasdaq
- ETNB Nasdaq
- Market Cap
- NYAX 1.7B
- ETNB 1.5B
- IPO Year
- NYAX N/A
- ETNB 2019
- Fundamental
- Price
- NYAX $49.93
- ETNB $8.87
- Analyst Decision
- NYAX Buy
- ETNB Strong Buy
- Analyst Count
- NYAX 7
- ETNB 10
- Target Price
- NYAX $42.00
- ETNB $27.22
- AVG Volume (30 Days)
- NYAX 12.1K
- ETNB 1.4M
- Earning Date
- NYAX 08-13-2025
- ETNB 08-07-2025
- Dividend Yield
- NYAX N/A
- ETNB N/A
- EPS Growth
- NYAX N/A
- ETNB N/A
- EPS
- NYAX 0.57
- ETNB N/A
- Revenue
- NYAX $348,663,000.00
- ETNB N/A
- Revenue This Year
- NYAX $31.84
- ETNB N/A
- Revenue Next Year
- NYAX $22.85
- ETNB N/A
- P/E Ratio
- NYAX $87.53
- ETNB N/A
- Revenue Growth
- NYAX 29.63
- ETNB N/A
- 52 Week Low
- NYAX $22.70
- ETNB $4.16
- 52 Week High
- NYAX $52.46
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- NYAX 65.62
- ETNB 43.45
- Support Level
- NYAX $47.88
- ETNB $8.46
- Resistance Level
- NYAX $50.87
- ETNB $9.47
- Average True Range (ATR)
- NYAX 0.79
- ETNB 0.46
- MACD
- NYAX 0.34
- ETNB -0.02
- Stochastic Oscillator
- NYAX 84.49
- ETNB 33.33
About NYAX Nayax Ltd.
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, and connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform, and integrated POS devices. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).